Evidence map›Paper›PMID 26846109›Full record

ArticleTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine2016

Low expression of PIDD is associated with cell proliferation and apoptosis in hepatocellular carcinoma.

Weidong Shi, Wei Huang, Yuyan Chen, Shusen Zhang, Pan Xu, Xiaoling Gu, Hui Fan, Jian Xu, Yongmei Chen, Runzhou Ni and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Downregulation of paraoxonase 3 contributes to aggressive human hepatocellular carcinoma progression and associates with poor prognosis.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016
    Trial
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Weidong ShiDepartment of Medical Oncology, Second People's Hospital of Nantong City, Nantong University, Nantong, 226001, Jiangsu, People's Republic of China.
Wei HuangDepartment of Gastroenterology, Affiliated Hospital of Nantong University, Nantong University, Nantong, 226001, Jiangsu, People's Republic of China.
Yuyan ChenClass 5, Grade 13, Clinical Medicine, Medical College, Nantong University, Nantong, 226001, Jiangsu, People's Republic of China.
Shusen ZhangDepartment of Gastroenterology, Affiliated Hospital of Nantong University, Nantong University, Nantong, 226001, Jiangsu, People's Republic of China.
Pan XuDepartment of Pathogen Biology, Medical College, Jiangsu Province Key Laboratory for Information and Molecular Drug Target, Nantong University, Nantong, 226001, Jiangsu, People's Republic of China.
Xiaoling GuDepartment of Pathogen Biology, Medical College, Jiangsu Province Key Laboratory for Information and Molecular Drug Target, Nantong University, Nantong, 226001, Jiangsu, People's Republic of China.
Hui FanDepartment of Medical Oncology, Second People's Hospital of Nantong City, Nantong University, Nantong, 226001, Jiangsu, People's Republic of China.
Jian XuDepartment of Medical Oncology, Second People's Hospital of Nantong City, Nantong University, Nantong, 226001, Jiangsu, People's Republic of China.
Yongmei ChenDepartment of Medical Oncology, Second People's Hospital of Nantong City, Nantong University, Nantong, 226001, Jiangsu, People's Republic of China.
Runzhou NiDepartment of Gastroenterology, Affiliated Hospital of Nantong University, Nantong University, Nantong, 226001, Jiangsu, People's Republic of China.
Cuihua LuDepartment of Gastroenterology, Affiliated Hospital of Nantong University, Nantong University, Nantong, 226001, Jiangsu, People's Republic of China. lch670608@sina.com.
Xiubing ZhangDepartment of Medical Oncology, Second People's Hospital of Nantong City, Nantong University, Nantong, 226001, Jiangsu, People's Republic of China. zhangxiubing2015@163.com.
Nantong University · CNAffiliated Hospital of Nantong University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

p53-induced death domain protein (PIDD) facilitates p53-dependent apoptosis through the interaction with components of the death receptor signaling pathways. However, the role of PIDD in hepatocellular carcinoma (HCC) development remains unknown. In this study, we investigated the expression pattern of PIDD in clinical HCC samples and adjacent non-cancerous tissues using immunohistochemistrical and Western blot analyses. The results showed that PIDD was lowly expressed in HCC tissues and HCC cell lines, compared with the adjacent non-tumorous tissues and LO2 normal hepatocytes. In addition, clinicopathological analysis showed that the expression of PIDD was closely related with multiple clinicopathological variables, such as American Joint Committee on Cancer (AJCC) stage, AFP, and poor prognosis of HCC. Univariate and multivariate survival analyses demonstrated that PIDD could serve as an independent prognostic factor to predict the survival of HCC patients. We used serum starvation-refeeding experiment to explore the involvement of PIDD in HCC cell cycle regulation. We found that PIDD was accumulated in growth-arrested HCC cells and was progressively decreased when cells entered into S phase. Moreover, flow cytometry and cell counting kit-8 (CCK-8) assays indicated that depleting the expression of PIDD could facilitate cell cycle progression and accelerate cell proliferation in HepG2 cells, while overexpression of PIDD could result in cell cycle arrest at G1 phase and hinder the cell proliferation in Hep3B cells. Finally, flow cytometry revealed that overexpression of PIDD slightly increased the apoptosis of HCC cells. Taken together, we concluded that PIDD may be a valuable prognostic marker and promising therapeutic target of HCC.

Indexed as

AdultAgedApoptosisCarcinoma, HepatocellularCell CycleCell DivisionCell Line, TumorDeath Domain Receptor Signaling Adaptor ProteinsFemaleHep G2 CellsHumansLiver NeoplasmsMaleMiddle AgedNeoplasm ProteinsPrognosisDeath Domain Receptor Signaling Adaptor ProteinsNeoplasm ProteinsPIDD1 protein, humanRecombinant Fusion ProteinsRNA, Small InterferingApoptosisHepatocellular carcinomaPIDDProliferation

Identifiers

PMID26846109
OpenAlexW2253467203

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.